Drug intelligence / Profile preview

18F-DualFAPi-7

Development stage: Preclinical
Lead developer: TetraKit Technologies
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-DualFAPi-7 (also known as 18F-DualFAPi or DualFAPi-7) is a preclinical-stage radiopharmaceutical diagnostic agent being developed by TetraKit Technologies. It is a fluorine-18 (18F) labeled dimeric fibroblast activation protein inhibitor (FAPi) designed for positron emission tomography (PET) imaging of FAP-expressing tumors. The agent utilizes a dimeric FAP-targeting scaffold to enhance tumor retention and binding affinity, coupled with a fluorine-18 beta-plus emitter to enable high-resolution PET imaging of the tumor microenvironment.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 18F-DualFAPi-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-DualFAPi-7.

Explore the full profile